An observational study in Supportive Care Needs of Caregivers, sponsored by Memorial Sloan Kettering Cancer Center. Recruiting at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-02.
Sponsored by Memorial Sloan Kettering Cancer Center · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Erdheim-Chester Disease with a site in United States — 7 open to participants now, 9 under way, none of them phase 3. Erdheim-Chester Disease · United States.
Among the 15 studies in Erdheim-Chester Disease with a site in United States, this one is one of 2 that started in 2019, is one of 8 observational ones, and was the 9th registered.
22 studies on the registry are indexed under Erdheim-Chester Disease; 11 are open to participants now.
Browse Erdheim-Chester Disease studies →7 of the 15 studies in Erdheim-Chester Disease with a site in United States are open now. Recruiting first, the newest first:
Mayo Clinic · Sites in United States
Ages 18+
Meyer Children's Hospital IRCCS · Sites in United States, France, Italy and 1 more country
Ages 7+
University of Alabama at Birmingham · Sites in United States
Ages 0–89
Carl Allen · Sites in United States
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 11 Erdheim-Chester Disease studies recruiting now, 8 (73%) set no upper age limit and 1 (9%) stops at 75 or younger; 7 take children under 18; 1 takes healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 4
First in 2011; this study’s year is marked. 2 started in 2019.
By drug class, each counting the studies that test any of its medicines:
Median enrollment 37 across the 7 interventional studies, 325 across the 8 observational. Of the 4 that completed or were terminated, 2 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 15 have an industry lead sponsor. The 10 most frequent:
Memorial Sloan Kettering Cancer Center is the lead sponsor of 1,964 studies on the registry; 325 are open to participants now.
Of its 135 completed or terminated interventional studies of FDA-regulated products, 71 (53%) have results posted.
Memorial Sloan Kettering Cancer Center has 4 studies filed under Erdheim-Chester Disease — fewer than ten, so there is no comparison to draw.
4 of the studies in Erdheim-Chester Disease with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03990428Memorial Sloan Kettering Cancer CenterSupportive Care Needs of Caregivers of People With Erdheim-Chester Disease and Other Histiocytic Diseases | 2027-06 |
| NCT05915208University of Alabama at BirminghamHistiocytic Disorder Follow-up Study | 2027-07 |
| NCT05093335Memorial Sloan Kettering Cancer CenterIn-Human CXCR4 Imaging of Hematologic and Solid Tumors Using [68Ga]-Pentixafor-PET | 2027-10 |
| NCT03329274Memorial Sloan Kettering Cancer CenterRegistry for Patients With Erdheim-Chester Disease and Other Histiocytoses | 2027-10 |
Add all 4 to your calendar (.ics) → With an account.
Among the 15 studies in Erdheim-Chester Disease with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is being done to answer the following question: What are the supportive care needs of informal caregivers of people with Erdheim-Chester disease and other histiocytic diseases?
A target sample of 120 ICs of patients with Erdheim-Chester Disease will be enrolled in this study. Additionally, a target sample of 50 ICs of patients with other histiocytic disorders will be enrolled.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
This is an observational study of informal caregivers (ICs) of patients with Erdheim-Chester Disease (ECD) and other histiocytic diseases. That will collect data cross-sectionally, at a single time point. Caregiver-reported data will be completed in the form of online surveys by the participants themselves using the Research Electronic Data Capture Platform \[RedCAP\] platform.
Behavioral: online surveys
Survey data about supportive care needs, mood, and the experience of IC's finding meaning and purpose in the caregiving experience.
Supportive Care Needs of informal caregivers
measured by the McGill Quality of Life in Life Threatening Illness - Family Carer Version (QLLTI-FC)
Time frame: 3 years
Plan to share: Yes — Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.
Supporting information: Statistical analysis plan, Informed consent form
Started Jun 2019 (actual). Primary completion is estimated for Jun 2027, 96 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Memorial Sloan Kettering Cancer Center →